BackArtiva Biotherapeutics Overview

Artiva Biotherapeutics Current Cash

Track Artiva Biotherapeutics's current cash ($21M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$20.95M
↓ 31.07% YoYΔ $-9.45M vs prior year quarter

Peer average

Loading

Artiva Biotherapeutics Current Cash History

Loading

Artiva Biotherapeutics vs. peers: Current Cash Comparison

Loading

Artiva Biotherapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Artiva Biotherapeutics (ARTV) FAQ

The latest current cash for ARTV is $21M as of March 2026. That compares with $30M in the prior-year period — down 31.1% year over year. Investors often review this figure alongside Artiva Biotherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, ARTV's current cash moved from $30M to $21M — a 31.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Artiva Biotherapeutics's operating scale or balance-sheet position.

A current cash figure of $21M for ARTV is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ARTV's current cash ($21M), review year-over-year change from $30M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.